More than 250 million people worldwide are chronically infected with the hepatitis B virus (HBV). In this Comment, members of the International Coalition to Eliminate HBV appraise the current policy environment and the need for appropriate cure research and preparedness to complement the WHO global elimination strategy, the HBV vaccine and the well-tolerated but poorly accessed therapy.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Razavi-Shearer, D. et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3, 383–403 (2018).
World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021. Towards ending viral hepatitis (WHO, 2016).
Papatheodoridis, G. V. et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J. Hepatol. 62, 956–967 (2015).
World Health Organization. Global hepatitis report 2017 (WHO, 2017).
Fattovich, G., Bortolotti, F. & Donato, F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48, 335–352 (2008).
United Nations. Transforming our world: the 2030 agenda for sustainable development. (UN General Assembly, 2015).
Stenberg, K. et al. Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries. Lancet Global Health 5, e875–e887 (2017).
Revill, P. et al. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 13, 239–248 (2016).
Nayagam, S. et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet. Infect. Dis. 16, 1399–1408 (2016).
Sugarman, J. et al. Ethics and hepatitis B cure research. Gut 66, 389–392 (2017).
The authors thank J. Pericàs and H. Nde for their input into an earlier draft of this article.
The authors declare no competing interests.
WHO/UNICEF birth-dose vaccination coverage estimates: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragebcg.html
About this article
Cite this article
Lazarus, J.V., Block, T., Bréchot, C. et al. The hepatitis B epidemic and the urgent need for cure preparedness. Nat Rev Gastroenterol Hepatol 15, 517–518 (2018). https://doi.org/10.1038/s41575-018-0041-6
A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification
Scientific Reports (2020)
Nature Reviews Gastroenterology & Hepatology (2019)